EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021
11/10/2021 - 08:00 AM
Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET
LYON, France, November 10, 20 21 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the markets close on Wednesday, November 17, 2021.
An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, Chief Executive Officer of EDAP U.S.A., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, November 18, 2021. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & Webcast Thursday, November 18 th @ 8:30am Eastern Time Domestic: 877-451-6152 International: 201-389-0879 Passcode: 13724088 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1503943&tp_key=7d846a9985
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com , and us.hifu-prostate.com .
CONTACTS: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.com
Investor Contact John Fraunces LifeSci Advisors, LLC 917-355-2395jfraunces@lifesciadvisors.com
EDAP Rankings
#3917 Ranked by Stock Gains
EDAP Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
About EDAP
global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke